Literature DB >> 25600578

Individualizing prophylaxis in hemophilia: a review.

Pia Petrini1, Leonard A Valentino, Alessandro Gringeri, Wendy M Re, Bruce Ewenstein.   

Abstract

Prophylaxis is considered optimal care for patients with severe hemophilia to prevent bleeding, including hemarthroses, which may cause arthropathy with chronic pain, occupational impairment and progressive loss of mobility. Questions remain regarding the optimal delivery of prophylaxis including how to individualize prophylaxis and optimize outcomes for each patient. Designing a prophylactic regimen for severe hemophilia must account for each patient's unique disease course, bleeding pattern, presence/absence of joint damage, pharmacokinetic profile, level of physical activity and adherence to treatment. Standard weight-based prophylaxis regimens and regimens optimized by bleeding phenotype (i.e., patients are 'allowed' to bleed to dose optimization) fail to prevent complications in many patients. Pharmacokinetic-guided dosing enables precise adjustment of dosing level and frequency to maintain adequate hemostatic levels and prevent bleeding. Optimal outcomes, such as reducing or eliminating hemorrhages, preventing or minimizing joint damage, and improving quality of life, can be achieved through an individualized care approach.

Entities:  

Keywords:  arthropathy; hemarthroses; hemophilia; personalized medicine; pharmacokinetics; prophylaxis

Mesh:

Year:  2015        PMID: 25600578     DOI: 10.1586/17474086.2015.1002465

Source DB:  PubMed          Journal:  Expert Rev Hematol        ISSN: 1747-4094            Impact factor:   2.929


  16 in total

Review 1.  Factor VIII replacement is still the standard of care in haemophilia A.

Authors:  Louis Aledort; Pier Mannuccio Mannucci; Wolfgang Schramm; Michael Tarantino
Journal:  Blood Transfus       Date:  2019-12-11       Impact factor: 3.443

2.  Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A.

Authors:  Xavier Delavenne; Yesim Dargaud; Edouard Ollier; Claude Négrier
Journal:  Br J Clin Pharmacol       Date:  2019-02-13       Impact factor: 4.335

3.  Development and Validation of a Population-Pharmacokinetic Model for Rurioctacog Alfa Pegol (Adynovate®): A Report on Behalf of the WAPPS-Hemo Investigators Ad Hoc Subgroup.

Authors:  Pierre Chelle; Cindy H T Yeung; Stacy E Croteau; Jennifer Lissick; Vinod Balasa; Christina Ashburner; Young Shil Park; Santiago Bonanad; Juan Eduardo Megías-Vericat; Azusa Nagao; Tung Wynn; Fernando Corrales-Medina; Huyen Tran; Anjali Sharathkumar; Meera Chitlur; Samuel Sarmiento; Andrea Edginton; Alfonso Iorio
Journal:  Clin Pharmacokinet       Date:  2020-02       Impact factor: 6.447

4.  Rurioctocog alfa pegol PK-guided prophylaxis in hemophilia A: results from the phase 3 PROPEL study.

Authors:  Robert Klamroth; Jerzy Windyga; Vlad Radulescu; Peter W Collins; Oleksandra Stasyshyn; Hishamshah Mohd Ibrahim; Werner Engl; Srilatha D Tangada; William Savage; Bruce Ewenstein
Journal:  Blood       Date:  2021-04-01       Impact factor: 22.113

Review 5.  Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.

Authors:  Lindsey A George; Rodney M Camire
Journal:  J Blood Med       Date:  2015-04-24

Review 6.  Damoctocog Alfa Pegol: A Review in Haemophilia A.

Authors:  Julia Paik; Emma D Deeks
Journal:  Drugs       Date:  2019-07       Impact factor: 9.546

7.  Efficacy, Safety and Pharmacokinetic Results of a Phase III, Open-Label, Multicenter Study with a Plasma-Derived Von Willebrand Factor (VWF)/Factor VIII (FVIII) Concentrate in Pediatric Patients <12 Years of Age with Hemophilia A (SWIFTLY-HA Study).

Authors:  Claudia Djambas Khayat; Genadi Iosava; Irina Romashevskaya; Oleksandra Stasyshyn; Marta Julia Lopez; Maria Teresa Pompa; Tobias Rogosch; Wilfried Seifert
Journal:  J Blood Med       Date:  2021-06-21

8.  Educational needs of hematologists and laboratory professionals regarding factor activity assays.

Authors:  Dorothy M Adcock; Mazi Rasulnia; Natalia Holot; David L Cooper
Journal:  J Blood Med       Date:  2018-04-13

9.  [Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2017-05-14

10.  Recombinant factor VIII Fc fusion protein for the treatment of severe haemophilia A: Final results from the ASPIRE extension study.

Authors:  Beatrice Nolan; Johnny Mahlangu; Ingrid Pabinger; Guy Young; Barbara A Konkle; Chris Barnes; Keiji Nogami; Elena Santagostino; K John Pasi; Liane Khoo; Bent Winding; Huixing Yuan; Joachim Fruebis; Dan Rudin; Johannes Oldenburg
Journal:  Haemophilia       Date:  2020-03-30       Impact factor: 4.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.